# Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

> **NCT04703920** · PHASE1 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Ovarian Carcinoma
- Metastic or Unresectable Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Talazoparib
- **DRUG:** Belinostat

## Key facts

- **NCT ID:** NCT04703920
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-04
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-01-02
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-01-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04703920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04703920, "Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04703920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*